SAN DIEGO--(BUSINESS WIRE)--Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC). This data is consistent with the favorable outcomes seen in the Phase 1 portion of the study, which assessed the safety, pharmacokinetics and efficacy of the combination.
